<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Periodontol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Periodontol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1600-051X</journal-id><journal-id journal-id-type="publisher-id">JCPE</journal-id><journal-title-group><journal-title>Journal of Clinical Periodontology</journal-title></journal-title-group><issn pub-type="ppub">0303-6979</issn><issn pub-type="epub">1600-051X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26250060</article-id><article-id pub-id-type="pmc">5054899</article-id><article-id pub-id-type="doi">10.1111/jcpe.12441</article-id><article-id pub-id-type="publisher-id">JCPE12441</article-id><article-categories><subj-group subj-group-type="overline"><subject>Randomized Clinical Trial</subject></subj-group><subj-group subj-group-type="heading"><subject>Periodontal Therapy</subject></subj-group></article-categories><title-group><article-title>Is progression of periodontitis relevantly influenced by systemic antibiotics? A clinical randomized trial</article-title><alt-title alt-title-type="left-running-head">Harks et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="jcpe12441-cr-0001" contrib-type="author"><name><surname>Harks</surname><given-names>Inga</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcpe12441-cr-0002" contrib-type="author"><name><surname>Koch</surname><given-names>Raphael</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jcpe12441-cr-0003" contrib-type="author"><name><surname>Eickholz</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcpe12441-cr-0004" contrib-type="author"><name><surname>Hoffmann</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jcpe12441-cr-0005" contrib-type="author"><name><surname>Kim</surname><given-names>Ti&#x02010;Sun</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jcpe12441-cr-0006" contrib-type="author"><name><surname>Kocher</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jcpe12441-cr-0007" contrib-type="author"><name><surname>Meyle</surname><given-names>Joerg</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jcpe12441-cr-0008" contrib-type="author"><name><surname>Kaner</surname><given-names>Do&#x0011f;an</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0008">
<sup>8</sup>
</xref><xref ref-type="aff" rid="jcpe12441-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="jcpe12441-cr-0009" contrib-type="author"><name><surname>Schlagenhauf</surname><given-names>Ulrich</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="jcpe12441-cr-0010" contrib-type="author"><name><surname>Doering</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="jcpe12441-cr-0011" contrib-type="author"><name><surname>Holtfreter</surname><given-names>Birte</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jcpe12441-cr-0012" contrib-type="author"><name><surname>Gravemeier</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcpe12441-cr-0013" contrib-type="author"><name><surname>Harmsen</surname><given-names>Dag</given-names></name><xref ref-type="aff" rid="jcpe12441-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcpe12441-cr-0014" contrib-type="author" corresp="yes"><name><surname>Ehmke</surname><given-names>Benjamin</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2418-6765</contrib-id><xref ref-type="aff" rid="jcpe12441-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jcpe12441-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Periodontology</named-content><institution>University Hospital M&#x000fc;nster</institution><named-content content-type="city">M&#x000fc;nster</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Institute of Biostatistics and Clinical Research</named-content><institution>University of M&#x000fc;nster</institution><named-content content-type="city">M&#x000fc;nster</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Periodontology</named-content><institution>Johann Wolfgang Goethe&#x02010;University Frankfurt</institution><named-content content-type="city">Frankfurt</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Periodontology</named-content><institution>TU Dresden</institution><named-content content-type="city">Dresden</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Section&#x000a0;of Periodontology</named-content><named-content content-type="organisation-division">Department of Conservative Dentistry</named-content><institution>University Hospital Heidelberg</institution><named-content content-type="city">Heidelberg</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Unit of Periodontology</named-content><institution>University Medicine Greifswald</institution><named-content content-type="city">Greifswald</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Department of Periodontology</named-content><institution>University of Giessen</institution><named-content content-type="city">Giessen</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Departments of Periodontology and Synoptic Dentistry</named-content><named-content content-type="organisation-division">Charit&#x000e9; Centrum 3</named-content><institution>Charit&#x000e9;&#x02010;Universit&#x000e4;tsmedizin Berlin</institution><named-content content-type="city">Berlin</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0009"><label><sup>9</sup></label><named-content content-type="organisation-division">Department of Periodontology</named-content><named-content content-type="organisation-division">Dental School</named-content><named-content content-type="organisation-division">Faculty of Health</named-content><institution>University of Witten/Herdecke</institution><named-content content-type="city">Witten</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0010"><label><sup>10</sup></label><named-content content-type="organisation-division">Department of Periodontology</named-content><institution>University Hospital W&#x000fc;rzburg</institution><named-content content-type="city">W&#x000fc;rzburg</named-content><country country="DE">Germany</country></aff><aff id="jcpe12441-aff-0011"><label><sup>11</sup></label><named-content content-type="organisation-division">Department of Psychoanalysis and Psychotherapy</named-content><institution>Medical University of Vienna</institution><named-content content-type="city">Vienna</named-content><country country="AT">Austria</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Address:<break/><italic>Benjamin Ehmke</italic><break/><italic>Department of Periodontology</italic><break/><italic>University Hospital M&#x000fc;nster</italic><break/><italic>Albert&#x02010;Schweitzer&#x02010;Campus 1</italic><break/><italic>Waldeyerstra&#x000df;e 30, 48149&#x000a0;M&#x000fc;nster</italic><break/><italic>Germany</italic><break/>
E&#x02010;mail: <email>ehmke@uni-muenster.de</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2015</year></pub-date><volume>42</volume><issue>9</issue><issue-id pub-id-type="doi">10.1111/jcpe.2015.42.issue-9</issue-id><fpage>832</fpage><lpage>842</lpage><history><date date-type="accepted"><day>16</day><month>7</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>Journal of Clinical Periodontology</italic> Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JCPE-42-832.pdf"/><abstract id="jcpe12441-abs-0001"><title>Abstract</title><sec id="jcpe12441-sec-0001"><title>Aim</title><p>We investigated the long&#x02010;term impact of adjunctive systemic antibiotics on periodontal disease progression. Periodontal therapy is frequently supplemented by systemic antibiotics, although its impact on the course of disease is still unclear.</p></sec><sec id="jcpe12441-sec-0002"><title>Material &#x00026; Methods</title><p>This prospective, randomized, double&#x02010;blind, placebo&#x02010;controlled multi&#x02010;centre trial comprising patients suffering from moderate to severe periodontitis evaluated the impact of rational adjunctive use of systemic amoxicillin 500&#x000a0;mg plus metronidazole 400&#x000a0;mg (3x/day, 7&#x000a0;days) on attachment loss. The primary outcome was the percentage of sites showing further attachment loss (<styled-content style="fixed-case">PSAL</styled-content>) &#x02265;1.3&#x000a0;mm after the 27.5&#x000a0;months observation period. Standardized therapy comprised mechanical debridement in conjunction with antibiotics or placebo administration, and maintenance therapy at 3&#x000a0;months intervals.</p></sec><sec id="jcpe12441-sec-0003"><title>Results</title><p>From 506 participating patients, 406 were included in the intention to treat analysis. Median <styled-content style="fixed-case">PSAL</styled-content> observed in placebo group was 7.8% compared to 5.3% in antibiotics group (Q25 4.7%/Q75 14.1%; Q25 3.1%/Q75 9.9%; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 respectively).</p></sec><sec id="jcpe12441-sec-0004"><title>Conclusions</title><p>Both treatments were effective in preventing disease progression. Compared to placebo, the prescription of empiric adjunctive systemic antibiotics showed a small absolute, although statistically significant, additional reduction in further attachment loss. Therapists should consider the patient's overall risk for periodontal disease when deciding for or against adjunctive antibiotics prescription.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jcpe12441-kwd-0001">amoxicillin/metronidazole</kwd><kwd id="jcpe12441-kwd-0002">attachment loss</kwd><kwd id="jcpe12441-kwd-0003">clinical relevance</kwd><kwd id="jcpe12441-kwd-0004">debridement</kwd><kwd id="jcpe12441-kwd-0005">outcome parameter</kwd><kwd id="jcpe12441-kwd-0006">periodontitis</kwd><kwd id="jcpe12441-kwd-0007"><styled-content style="fixed-case">randomised controlled trial</styled-content></kwd><kwd id="jcpe12441-kwd-0008">systemic antibiotics</kwd></kwd-group><funding-group><award-group><funding-source>German Research Foundation (Deutsche Forschungsgemeinschaft (DFG))</funding-source><award-id>EH 365 1&#x02010;1</award-id></award-group></funding-group><funding-group><award-group><funding-source>Open Access Publication Fund of the University of M&#x000fc;nster</funding-source></award-group></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jcpe12441</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:07.10.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jcpe12441-cit-1001">
<string-name>
<surname>Harks</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Eickholz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>T&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Kocher</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Meyle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kaner</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schlagenhauf</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Doering</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Holtfreter</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gravemeier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Harmsen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ehmke</surname>
<given-names>B</given-names>
</string-name>. <article-title>Is progression of periodontitis relevantly influenced by systemic antibiotics? A clinical randomized trial</article-title>. <source>J Clin Periodontol</source>
<year>2015</year>; <volume>42</volume>: <fpage>832</fpage>&#x02013;<lpage>842</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/jcpe.12441">10.1111/jcpe.12441</ext-link>
<pub-id pub-id-type="pmid">26250060</pub-id></mixed-citation>
</p></notes><notes><fn-group id="jcpe12441-ntgp-0001"><fn id="jcpe12441-note-0001"><p>
<bold>Conflict of interest and sources of funding statement</bold>
</p><p>The authors declare that there are no conflicts of interest in this study. The study was exclusively supported by a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft (DFG): EH 365 1&#x02010;1), from the authors' institutions, and the Open Access Publication Fund of the University of M&#x000fc;nster. No writing assistance other than copy editing was provided.</p></fn><fn id="jcpe12441-note-0002"><p>ISRCTN64254080, Clinical Trials.gov NCT00707369.</p></fn></fn-group></notes></front><body><p>Periodontitis is an inflammatory disease caused by a microbial biofilm (Socransky et&#x000a0;al. <xref rid="jcpe12441-bib-0034" ref-type="ref">1998</xref>, Paster et&#x000a0;al. <xref rid="jcpe12441-bib-0032" ref-type="ref">2001</xref>, Darveau <xref rid="jcpe12441-bib-0006" ref-type="ref">2010</xref>), characterized by periodontal pocket formation, attachment loss and loss of supporting alveolar bone. Periodontally compromised teeth lose function and may have to be extracted, which often requires costly prosthetic rehabilitations. In industrialized countries, approximately 50% of the adult population suffers from moderate or severe periodontits (Holtfreter et&#x000a0;al. <xref rid="jcpe12441-bib-0019" ref-type="ref">2010</xref>, Eke et&#x000a0;al. <xref rid="jcpe12441-bib-0010" ref-type="ref">2012</xref>). Basic periodontal therapy usually comprises mechanical debridement of the teeth, that is the disruption of biofilm, followed by lifelong maintenance therapy (AAP <xref rid="jcpe12441-bib-0001" ref-type="ref">2000</xref>).</p><p>Mechanical debridement in patients with moderate to severe periodontitis can be supplemented with systemic antibiotics, such as amoxicillin and metronidazole. The rationale for the adjunctive use of antibiotics is to exert an antimicrobial effect at sites inaccessible to mechanical therapy, and possibly to suppress periodontal pathogens (Pavici&#x00107; et&#x000a0;al. <xref rid="jcpe12441-bib-0033" ref-type="ref">1994</xref>, Flemmig et&#x000a0;al. <xref rid="jcpe12441-bib-0013" ref-type="ref">1998</xref>). However, the uncritical use of antibiotics could increase bacterial resistances (Spellberg et&#x000a0;al. <xref rid="jcpe12441-bib-0035" ref-type="ref">2008</xref>). Therefore, a critical appraisal of routine prescription and its clinical relevance is mandatory (Man&#x02010;Son&#x02010;Hing et&#x000a0;al. <xref rid="jcpe12441-bib-0027" ref-type="ref">2002</xref>). Systematic reviews state that prescription of adjunctive systemic antibiotics improved clinical conditions, but due to data inhomogeneity, final recommendations for its routine use are difficult. Methodological weaknesses and the heterogeneous design of existing studies such as small sample size, patients with severe disease only and weak endpoints for determination of disease progression were criticized (Herrera et&#x000a0;al. <xref rid="jcpe12441-bib-0018" ref-type="ref">2002</xref>, Haffajee et&#x000a0;al. <xref rid="jcpe12441-bib-0016" ref-type="ref">2003</xref>). Most trials substantiated the relevance of the superior outcomes of adjunctive antibiotic therapy in periodontal treatment on the basis of statistical significance, nevertheless it remains questionable if these differences are clinically relevant. Therefore, there is a need for trials on larger patient samples with sufficient observation periods and clinically relevant endpoints.</p><p>This large multi&#x02010;centre trial aimed at determining the efficacy of systemic antibiotics on periodontal disease progression. Our hypothesis was that empiric systemic adjunctive antibiotics reduce the proportion of sites exhibiting further disease progression.</p><sec id="jcpe12441-sec-0006"><title>Patients and Methods</title><sec id="jcpe12441-sec-0007"><title>Study design</title><p>The study was a prospective, randomized, stratified, double&#x02010;blind, multi&#x02010;centre (eight university hospital centres) trial with parallel&#x02010;group design (Harks et&#x000a0;al. <xref rid="jcpe12441-bib-0017" ref-type="ref">2014</xref>). Patients with untreated moderate to severe chronic and aggressive periodontitis were included (for inclusion/exclusion criteria see Table&#x000a0;<xref rid="jcpe12441-tbl-0001" ref-type="table-wrap">1</xref>). The institutional review boards of the participating centres approved the protocol and all patients provided written informed consent. An independent data and safety monitoring board reviewed the safety data throughout the trial. The trial was registered (Current Controlled Trials: ISRCTN64254080; Clinical Trials.gov Identifier NCT00707369).</p><table-wrap id="jcpe12441-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Inclusion, exclusion and withdrawal criteria</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Inclusion criteria</th><th align="left" valign="top" rowspan="1" colspan="1">Exclusion criteria</th><th align="left" valign="top" rowspan="1" colspan="1">Withdrawal criteria</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="jcpe12441-list-0001"><list-item><p>CPITN of IV in at least one sextant</p></list-item><list-item><p>Age range from 18 to 75&#x000a0;years</p></list-item><list-item><p>Clinical and radiographic signs of moderate (clinical attachment loss of 3&#x02013;4&#x000a0;mm) to severe (clinical attachment loss 5&#x000a0;mm or more) chronic or aggressive periodontitis</p></list-item><list-item><p>At least 10 natural teeth in&#x000a0;situ</p></list-item><list-item><p>Pocket probing depths (PPDs) of &#x02265;6&#x000a0;mm at a minimum of four teeth</p></list-item><list-item><p>Willingness to participate and to be available at any time as required for participation</p></list-item><list-item><p>Willingness to abstain from using antimicrobial mouth&#x02010;rinse during the study except for those explicitly prescribed</p></list-item><list-item><p>Informed consent signed by the patient</p></list-item><list-item><p>Sufficient knowledge of the German language</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="jcpe12441-list-0002"><list-item><p>Confirmed or assumed allergies or hypersensitive skin reactions to amoxicillin and/or metronidazole</p></list-item><list-item><p>show confirmed lactose intolerance (parents or siblings)</p></list-item><list-item><p>Down Syndrome</p></list-item><list-item><p>Suffer from AIDS/HIV</p></list-item><list-item><p>Take systematic medication affecting the periodontal conditions, e.g. phenytoine, nifedipine, and/or steroid drugs</p></list-item><list-item><p>Professional periodontal therapy during the past 6&#x000a0;months prior to baseline</p></list-item><list-item><p>Require an antibiotic coverage for dental treatments</p></list-item><list-item><p>Undergoing or require an extensive dental or orthodontic treatment</p></list-item><list-item><p>Pregnant or breastfeeding</p></list-item><list-item><p>Rampant caries</p></list-item><list-item><p>Oral or extra oral piercing in or around the oral cavity with ornaments or accessory jewellery</p></list-item><list-item><p>Dental students or dental professionals</p></list-item><list-item><p>Participated in a clinical dental trial during the 6&#x000a0;months preceding the study</p></list-item><list-item><p>Cognitive deficits</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="jcpe12441-list-0003"><list-item><p>Admitted offending against or are no longer willing to follow the protocol</p></list-item><list-item><p>Do not keep the appointments</p></list-item><list-item><p>Have serious adverse reactions related to the medications prescribed in the trial (i.e. allergic reactions to the prescribed antibiotics)</p></list-item></list>
</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Per patient, 12 visits over 27.5&#x000a0;months were scheduled (Fig.&#x000a0;<xref rid="jcpe12441-fig-0001" ref-type="fig">1</xref>a). The sponsor's safety desk was responsible for serious adverse events (SAE) management and fulfilled safety reporting obligations. Participants were divided into four strata according to the extent of periodontal disease [localized: &#x0003c;38%; generalized: &#x02265;38% of teeth with pocket probing depths (PPD) &#x02265;6&#x000a0;mm] and smoking habit [non&#x02010;/light smoker: &#x0003c;7&#x000a0;ppm CO in exhaled air; moderate to heavy smoker: &#x02265;7&#x000a0;ppm (Bedfont&#x02010;Smokerlyzer<sup>&#x000ae;</sup>, Bedfont, UK)]. The four strata were defined as follows: stratum 1 (localized periodontal disease, non&#x02010;/light smoker), stratum 2 (generalized periodontal disease, non&#x02010;/light smoker), stratum 3 (localized periodontal disease, smoker) and stratum 4 (generalized periodontal disease, smoker).</p><fig fig-type="Figure" xml:lang="en" id="jcpe12441-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study design and flow. (a) The timeline for the trial is illustrated. After screening (visit1), baseline measurements and subsequent randomization was performed (visit 2). After dental biofilms were disrupted during initial treatment (mechanical debridement), blinded amoxicillin/metronidazole or placebo was dispensed (visit 3). Re&#x02010;evaluation (visit 4) was performed 3.5&#x000a0;months after visit 2. Maintenance therapy (mechanical debridement) was carried out at 3&#x000a0;months intervals (visits 5 through 12). Measurements were also conducted 9.5, 15.5, 21.5 and 27.5&#x000a0;months after visit 2 (visits 6, 8, 10 and 12). (b) Sequence of screening, randomization, drop outs, serious adverse events and follow&#x02010;up of participants are illustrated. From 506 randomized patients, 93 dropped out over the 27.5&#x000a0;months study period. Overall, 406 patients were included in the intention to treat analyses, but, due to incomplete medication intake, only 345 patients were included into the per&#x02010;protocol analysis.</p></caption><graphic id="nlm-graphic-1" xlink:href="JCPE-42-832-g001"/></fig></sec><sec id="jcpe12441-sec-0008"><title>Randomization</title><p>Quad&#x02010;block randomization lists were computer generated for each stratum per centre by a statistician otherwise not being involved in trial affairs. Randomization lists for participating centres were stored exclusively at the study centre. To allocate a patient into a treatment group, the central study nurse was informed about the patients' disease extent and CO level in exhaled air by a phone call. Due to this information, patients were assigned to one of the four strata and thereafter allocated into one treatment group according to the stratum's randomized list. Every position on the randomization list corresponded to a medication package number corresponding to a pre&#x02010;packed medication box. The central study nurse informed the respective centre about the corresponding medication box. Labelled trial medication was stored at the participating centres.</p></sec><sec id="jcpe12441-sec-0009"><title>Periodontal therapy and intervention</title><p>Within 1.5&#x000a0;months after baseline examination (visit 2), patients received supra&#x02010; and subgingival debridement in up to two sessions on two consecutive days (visit 3, Fig.&#x000a0;<xref rid="jcpe12441-fig-0001" ref-type="fig">1</xref>a). All mechanical therapy was performed with different hand instruments and/or machine driven scalers. After completion of mechanical therapy, in the antibiotics group patients received two empiric antibiotics [amoxicillin 3H<sub>2</sub>O 574&#x000a0;mg (Amoxicillin&#x02010;ratiopharm 500&#x000a0;mg<sup>&#x000ae;</sup>, Ratiopharm, Germany); metronidazole 400&#x000a0;mg (Flagyl<sup>&#x000ae;</sup> 400, Sanofi&#x02010;Aventis, Germany)] and placebo group patients two placebo drugs, each to be taken three times a day for 7&#x000a0;days. Medication was repacked in neutral capsules with identical appearance by the university pharmacy in Dresden, Germany. Each patient received two medication packages with consecutive numbers according to the randomization list. The patients kept a medication diary to document drug adherence. Patients were informed about the medications' side effects according to the package inserts of amoxicillin and metronidazole.</p><p>Re&#x02010;evaluation (visit 4) was performed 3.5&#x000a0;months after baseline. Thereafter, all patients received maintenance therapy, including full&#x02010;mouth supra&#x02010; and subgingival debridement and oral hygiene instruction at 3&#x000a0;months intervals (visits 5 through 12, Fig.&#x000a0;<xref rid="jcpe12441-fig-0001" ref-type="fig">1</xref>a). Sites with PPD &#x02265;4&#x000a0;mm also received subgingival re&#x02010;debridement. All treatments were performed by blinded qualified dentists or dental hygienists.</p></sec><sec id="jcpe12441-sec-0010"><title>Examinations and endpoints</title><p>Full&#x02010;mouth periodontal measurements were carried out at six sites of each tooth by blinded examiners not involved in periodontal therapy. Examiners were calibrated for relative attachments level (RAL) measurements 3&#x000a0;months before examining participants and annually thereafter (Harks et&#x000a0;al. <xref rid="jcpe12441-bib-0017" ref-type="ref">2014</xref>). RAL measurements, corresponding to the distance from occlusal surface to the bottom of the periodontal pocket, were performed in duplicate with an electronic pressure&#x02010;sensitive probe (Florida Disk probe, Gainesville, FL, USA) in increments of 0.2&#x000a0;mm. The difference between baseline and follow&#x02010;up RAL readings described the changes of the clinical attachment level (gain or loss of tooth supporting tissue).</p><p>The primary outcome was the proportion of sites per patient with new clinical attachment loss (PSAL) &#x02265;1.3&#x000a0;mm between baseline and the 27.5&#x000a0;months visit. The &#x02265;1.3&#x000a0;mm threshold was considered clinically relevant, because conversely, 1.3&#x000a0;mm gain in clinical attachment after periodontal therapy is considered a relevant outcome, too (Cobb <xref rid="jcpe12441-bib-0004" ref-type="ref">1996</xref>). Attachment loss was used as outcome variable instead of attachment gain, because it is associated with tooth loss, which constitutes a true endpoint (Hujoel et&#x000a0;al. <xref rid="jcpe12441-bib-0020" ref-type="ref">1999</xref>). Therefore, the presence of attachment loss is tantamount to disease progression. The following secondary endpoints were assessed exploratorily (Florida standard probe, Gainesville, FL, USA): PPD, clinical attachment, gingival bleeding on probing (Lang et&#x000a0;al. <xref rid="jcpe12441-bib-0022" ref-type="ref">1990</xref>) and supragingival plaque (O'Leary et&#x000a0;al. <xref rid="jcpe12441-bib-0031" ref-type="ref">1972</xref>). All measurements were performed at &#x0201c;baseline&#x0201d; (visit 2), after 3.5&#x000a0;months (re&#x02010;evaluation, visit 4), and at 9.5, 15.5, 21.5 and 27.5&#x000a0;months &#x0201c;follow&#x02010;ups&#x0201d; (visits 6, 8, 10 and 12; Fig.&#x000a0;<xref rid="jcpe12441-fig-0001" ref-type="fig">1</xref>a).</p><p>The medical history and the body mass index were assessed at visit 1, and non&#x02010;fasting blood samples were drawn to determine the HbA1c levels (visits 1, 8 and 12). As an indicator of subjective oral health perception, the German version of the Oral Health Impact Profile (OHIP&#x02010;G 49) was recorded at visits 1, 8 and 12 (John et&#x000a0;al. <xref rid="jcpe12441-bib-0021" ref-type="ref">2002</xref>).</p></sec><sec id="jcpe12441-sec-0011"><title>Statistics</title><p>Former study results were used for sample size estimation and we expected the percentage of sites per patient showing new attachment loss during the trial period of at least 15% in the placebo and 7% in the antibiotics group (Berglundh et&#x000a0;al. <xref rid="jcpe12441-bib-0002" ref-type="ref">1998</xref>, Tinoco et&#x000a0;al. <xref rid="jcpe12441-bib-0036" ref-type="ref">1998</xref>, Ehmke et&#x000a0;al. <xref rid="jcpe12441-bib-0008" ref-type="ref">2005</xref>, Guerrero et&#x000a0;al. <xref rid="jcpe12441-bib-0015" ref-type="ref">2005</xref>). The confirmatory objective was to detect a clinically relevant difference of 15% (placebo group) and 7% (antibiotics group) in PSAL with standard deviation (SD) = 25%, type&#x02010;I error rate <italic>&#x003b1;&#x000a0;</italic>=&#x000a0;0.05 and power 1&#x02013;<italic>&#x003b2;&#x000a0;</italic>=&#x000a0;0.8. In total, 175 evaluable patients per group were required. The hypothesis was that oral administration of systemic adjunctive antibiotics will reduce the proportion of sites exhibiting PSAL &#x02265;1.3&#x000a0;mm from 15% to 7%.</p><p>Due to the assumption of a non&#x02010;normally distributed primary endpoint (PSAL), the two&#x02010;sided stratified Wilcoxon test (van Elteren test) was applied and a <italic>p</italic>&#x02010;value &#x02264;0.05 was regarded as statistically significant (van Elteren <xref rid="jcpe12441-bib-0011" ref-type="ref">1960</xref>). Secondary endpoints were analysed at each visit using van Elteren tests, that is the percentage of sites showing PPD &#x02265;5&#x000a0;mm or attachment gain, mean PPD, mean attachment level, bleeding on probing and supragingival plaque index. The resulting <italic>p</italic>&#x02010;values were intended to be exploratory instead of confirmatory, and represent a metric of evidence against the respective null hypothesis of no effect. No adjustment for multiple testing was performed and <italic>p</italic>&#x02010;values &#x02264;0.05 were considered as statistically noticeable.</p><p>Standard descriptive analyses were performed. Variables regarded as normally distributed were presented as mean&#x000a0;&#x000b1;&#x000a0;SD; non&#x02010;normally distributed variables were described by median (25% quantile Q25/75% quantile Q75). Categorical variables were reported as absolute and relative frequencies compared with Fisher's exact tests. Mean periodontal measures were computed as percentages of sites per person and then averaged across all participants within each treatment group.</p><p>In addition, PPD values on site level were analysed according to their baseline probing depth category (&#x02264;3.4&#x000a0;mm, 3.5&#x02013;6.4&#x000a0;mm, &#x02265;6.5&#x000a0;mm) and the proportion of patients showing PPD &#x02265;5&#x000a0;mm at &#x02264;4 sites was calculated. Cohen's D was calculated to assess the effect size in mean differences between the treatment groups for changes in the OHIP scores.</p><p>All efficacy analyses were based on the intention to treat principle, comparing groups according to the randomly assigned treatment and strata. Primary and secondary endpoints were evaluated in the per&#x02010;protocol collective at each visit. A sensitivity analysis was performed with PSAL &#x02265;2&#x000a0;mm.</p><p>Statistical analyses were performed using Version 9.3 of the SAS System for Windows software (SAS Institute Inc., 100 SAS Campus DriveCary, NC, USA).</p></sec></sec><sec id="jcpe12441-sec-0012"><title>Results</title><sec id="jcpe12441-sec-0013"><title>Patient enrolment</title><p>Patient recruitment started in July 2008 and finished in October 2009. Overall 3261 patients were screened, 1003 met the inclusion criteria, 461 declined to participate, 36 dropped out before randomization and 506 were randomized (Fig.&#x000a0;<xref rid="jcpe12441-fig-0001" ref-type="fig">1</xref>b). All follow&#x02010;up examinations were finished by December 2011. The study database was closed in March 2012.</p><p>Of 506 randomized patients, 406 (intention to treat collective, ITT; placebo: <italic>n</italic>&#x000a0;=&#x000a0;200, antibiotics <italic>n</italic>&#x000a0;=&#x000a0;206) finished the therapy regime by visit 12 (drop out <italic>n</italic>&#x000a0;=&#x000a0;100; 19.8%). All patients who followed the study timeline according to the protocol and took all tablets within 6 through 8&#x000a0;days according to their medication diaries were included in the per&#x02010;protocol collective (PP, 345 patients, placebo: <italic>n</italic>&#x000a0;=&#x000a0;175, antibiotics: <italic>n</italic>&#x000a0;=&#x000a0;170). For baseline demographic and clinical characteristics see Tables&#x000a0;<xref rid="jcpe12441-tbl-0002" ref-type="table-wrap">2</xref> and <xref rid="jcpe12441-tbl-0003" ref-type="table-wrap">3</xref>, respectively. Due to the clinical and demographic characteristics, the patients were rather a sample of chronic periodontitis.</p><table-wrap id="jcpe12441-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Patient demography at baseline (visit 2) by treatment groups and collectives<xref ref-type="fn" rid="jcpe12441-note-0003">a</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Intention to treat collective</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Per&#x02010;protocol collective</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Placebo group</th><th align="left" valign="top" rowspan="1" colspan="1">Antibiotics group</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo group</th><th align="left" valign="top" rowspan="1" colspan="1">Antibiotics group</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">206</td><td align="left" rowspan="1" colspan="1">175</td><td align="left" rowspan="1" colspan="1">170</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x02013; yr</td><td align="left" rowspan="1" colspan="1">50.5&#x000a0;&#x000b1;&#x000a0;10.5</td><td align="left" rowspan="1" colspan="1">52.6&#x000a0;&#x000b1;&#x000a0;10.4</td><td align="left" rowspan="1" colspan="1">52.3&#x000a0;&#x000b1;&#x000a0;10.8</td><td align="left" rowspan="1" colspan="1">53.5&#x000a0;&#x000b1;&#x000a0;10.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex &#x02013; no. (%)</td><td align="left" rowspan="1" colspan="1">101 (50.4)</td><td align="left" rowspan="1" colspan="1">102 (49.6)</td><td align="left" rowspan="1" colspan="1">87 (49.7)</td><td align="left" rowspan="1" colspan="1">85 (50.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Active smokers &#x02013; no. (%)</td><td align="left" rowspan="1" colspan="1">53 (26.5)</td><td align="left" rowspan="1" colspan="1">61 (29.6)</td><td align="left" rowspan="1" colspan="1">44 (25.1)</td><td align="left" rowspan="1" colspan="1">49 (28.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Former smokers &#x02013; no. (%)</td><td align="left" rowspan="1" colspan="1">76 (44.7)</td><td align="left" rowspan="1" colspan="1">75 (44.4)</td><td align="left" rowspan="1" colspan="1">63 (36)</td><td align="left" rowspan="1" colspan="1">64 (37.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">CO non&#x02010;smoker &#x02013; ppm</td><td align="left" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">CO smoker&#x02013; ppm</td><td align="left" rowspan="1" colspan="1">16.4&#x000a0;&#x000b1;&#x000a0;10.3</td><td align="left" rowspan="1" colspan="1">13.5&#x000a0;&#x000b1;&#x000a0;10.4</td><td align="left" rowspan="1" colspan="1">13.7&#x000a0;&#x000b1;&#x000a0;8.7</td><td align="left" rowspan="1" colspan="1">13.5&#x000a0;&#x000b1;&#x000a0;10.5</td></tr><tr><td align="left" colspan="5" rowspan="1">Medication intake<xref ref-type="fn" rid="jcpe12441-note-0004">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">21</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Range Min./Max.</td><td align="left" rowspan="1" colspan="1">3/24</td><td align="left" rowspan="1" colspan="1">0/24</td><td align="left" rowspan="1" colspan="1">18/23</td><td align="left" rowspan="1" colspan="1">18/23</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c &#x0003e;6.5% (Diabetes) &#x02013; no.</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c &#x02013; %</td><td align="left" rowspan="1" colspan="1">5.4&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left" rowspan="1" colspan="1">5.5&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left" rowspan="1" colspan="1">5.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left" rowspan="1" colspan="1">5.5&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index &#x02013; kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">25.9&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="left" rowspan="1" colspan="1">25.7&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="left" rowspan="1" colspan="1">25.9&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="left" rowspan="1" colspan="1">25.5&#x000a0;&#x000b1;&#x000a0;4.5</td></tr></tbody></table><table-wrap-foot><fn id="jcpe12441-note-0003"><label>a</label><p>Continuous variables are shown as mean&#x000a0;&#x000b1;&#x000a0;SD, categorical variables are shown as absolute and relative frequencies. No statistically noticeable differences were noted between the groups at baseline either in the intention to treat collective or in the per&#x02010;protocol collective.</p></fn><fn id="jcpe12441-note-0004"><label>b</label><p>Total number of time points with medication intake; every patient was advised to take two tablets (amoxicillin plus metronidazole or two placebo tablets) 21 times.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="jcpe12441-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Patient periodontal characteristics at baseline (visit 2) and 27.5&#x000a0;months follow&#x02010;up (visit 12)<xref ref-type="fn" rid="jcpe12441-note-0005">a</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo group</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Antibiotics group</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">Baseline</th><th align="center" valign="top" rowspan="1" colspan="1">27.5&#x000a0;months</th><th align="center" valign="top" rowspan="1" colspan="1">Baseline</th><th align="center" valign="top" rowspan="1" colspan="1">27.5&#x000a0;months</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">
<italic>Intention to Treat Collective</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total no. of teeth</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.8&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.0&#x000a0;&#x000b1;&#x000a0;4.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.4&#x000a0;&#x000b1;&#x000a0;4.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">23.8&#x000a0;&#x000b1;&#x000a0;4.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean probing depth &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.5&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.7&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.4&#x000a0;&#x000b1;&#x000a0;0.5<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" colspan="5" rowspan="1">Proportion of probing depths</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% &#x02264;3.4 &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">59.2&#x000a0;&#x000b1;&#x000a0;18.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">79.1&#x000a0;&#x000b1;&#x000a0;15.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">58.3&#x000a0;&#x000b1;&#x000a0;16.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">85.8&#x000a0;&#x000b1;&#x000a0;12.6<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% 3.5&#x02013;6.4 &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">32.9&#x000a0;&#x000b1;&#x000a0;12.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">18.1&#x000a0;&#x000b1;&#x000a0;12.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">34.0&#x000a0;&#x000b1;&#x000a0;12.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.2&#x000a0;&#x000b1;&#x000a0;11.6<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% &#x02265;6.5 &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.9&#x000a0;&#x000b1;&#x000a0;8.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.8&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.6&#x000a0;&#x000b1;&#x000a0;8.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.9&#x000a0;&#x000b1;&#x000a0;1.8<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean attachment Level &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.1&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.7&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.1&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.4&#x000a0;&#x000b1;&#x000a0;0.9<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sites with gingival bleeding &#x02013;%</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">34.2&#x000a0;&#x000b1;&#x000a0;18.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19.6&#x000a0;&#x000b1;&#x000a0;14.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">36.3&#x000a0;&#x000b1;&#x000a0;19.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.1&#x000a0;&#x000b1;&#x000a0;12.6<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sites with detectable plaque&#x02013;%</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">36.5&#x000a0;&#x000b1;&#x000a0;24.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">37.3&#x000a0;&#x000b1;&#x000a0;23.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">38.7&#x000a0;&#x000b1;&#x000a0;24.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">39.3&#x000a0;&#x000b1;&#x000a0;24.6</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Per&#x02010;Protocol Collective</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total no. of teeth</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.0&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.1&#x000a0;&#x000b1;&#x000a0;4.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.5&#x000a0;&#x000b1;&#x000a0;4.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">23.8&#x000a0;&#x000b1;&#x000a0;4.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean probing depth &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.5&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.5&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.3&#x000a0;&#x000b1;&#x000a0;0.5<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" colspan="5" rowspan="1">Proportion of probing depths</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% &#x02264;3.4 &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">59.9&#x000a0;&#x000b1;&#x000a0;17.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">79.9&#x000a0;&#x000b1;&#x000a0;14.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">59.6&#x000a0;&#x000b1;&#x000a0;16.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">85.9&#x000a0;&#x000b1;&#x000a0;12.6<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% 3.5&#x02013;6.4 &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">32.2&#x000a0;&#x000b1;&#x000a0;12.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">17.4&#x000a0;&#x000b1;&#x000a0;12.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">33.0&#x000a0;&#x000b1;&#x000a0;11.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">13.2&#x000a0;&#x000b1;&#x000a0;11.7<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% &#x02265;6.5 &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.9&#x000a0;&#x000b1;&#x000a0;8.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.7&#x000a0;&#x000b1;&#x000a0;4.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.4&#x000a0;&#x000b1;&#x000a0;8.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.9&#x000a0;&#x000b1;&#x000a0;1.6<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean attachment Level &#x02013; mm</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.1&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.6&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4.0&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.0&#x000a0;&#x000b1;&#x000a0;0.9<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sites with gingival bleeding &#x02013; %</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">34.3&#x000a0;&#x000b1;&#x000a0;16.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">18.9&#x000a0;&#x000b1;&#x000a0;14.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">36.4&#x000a0;&#x000b1;&#x000a0;19.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.8&#x000a0;&#x000b1;&#x000a0;12.0<xref ref-type="fn" rid="jcpe12441-note-0006">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sites with detectable plaque &#x02013; %</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">35.8&#x000a0;&#x000b1;&#x000a0;23.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">36.7&#x000a0;&#x000b1;&#x000a0;23.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">38.2&#x000a0;&#x000b1;&#x000a0;24.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">38.9&#x000a0;&#x000b1;&#x000a0;24.7</td></tr></tbody></table><table-wrap-foot><fn id="jcpe12441-note-0005"><label>a</label><p>Continuous variables are shown as mean &#x000b1; SD. No statistically noticeable differences were noted between the groups at baseline either in the intention to treat collective or in the per&#x02010;protocol collective.</p></fn><fn id="jcpe12441-note-0006"><label>b</label><p>Statistically noticeable differences between placebo and antibiotic groups after 27.5&#x000a0;months, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; van Elteren Test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jcpe12441-sec-0014"><title>Primary outcome</title><p>In the ITT&#x02010;collective, the median PSAL &#x02265;1.3&#x000a0;mm over the 27.5&#x000a0;months period was 7.8% (Q25 4.7%/Q75 14.1%) in the placebo <italic>versus</italic> 5.3% (Q25 3.1%/Q75 9.9%) in the antibiotics group. The difference between the patient groups was significant (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Fig.&#x000a0;<xref rid="jcpe12441-fig-0002" ref-type="fig">2</xref>a, Table&#x000a0;<xref rid="jcpe12441-tbl-0004" ref-type="table-wrap">4</xref>). For results of the PP&#x02010;collective see Table&#x000a0;<xref rid="jcpe12441-tbl-0004" ref-type="table-wrap">4</xref>.</p><fig fig-type="Figure" xml:lang="en" id="jcpe12441-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Changes in main clinical parameters over the course of the study. (a) Percentage of sites with attachment loss (<styled-content style="fixed-case">PSAL</styled-content>) &#x02265;1.3&#x000a0;mm displayed for the placebo and antibiotics (amoxicillin/metronidazole) group over the course of the study. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, from stratified van Elteren tests. (b) The percentage of sites with pocket probing depth (<styled-content style="fixed-case">PPD</styled-content>) &#x02265;5&#x000a0;mm are displayed for the placebo and antibiotics (amoxicillin/metronidazole) group over the course of the study. At baseline (visit 2), the percentage of <styled-content style="fixed-case">PPD</styled-content> &#x02265;5&#x000a0;mm was not different in both groups (<italic>p</italic>&#x000a0;=&#x000a0;0.66, stratified van Elteren test). Beginning with visit 4, although both groups achieved clinically favourable levels, the antibiotics group patients showed statistically noticeable lower presence of <styled-content style="fixed-case">PPD</styled-content> &#x02265;5&#x000a0;mm compared to placebo patients. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001.</p></caption><graphic id="nlm-graphic-3" xlink:href="JCPE-42-832-g002"/></fig><table-wrap id="jcpe12441-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>The proportion (%) of sites per patient with new clinical attachment loss (PSAL) &#x02265;1.3&#x000a0;mm between baseline (visit 2) and the 27.5&#x000a0;months follow&#x02010;up (visit 12). PSAL is also analysed according to the baseline probing depth category (&#x02264;3.4&#x000a0;mm, 3.5&#x02013;6.4&#x000a0;mm, &#x02265;6.5&#x000a0;mm) of the site. PSAL is described by median (25% quantile Q25/75% quantile Q75)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Initial pocket probing depths</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo group</th><th align="center" colspan="2" valign="top" rowspan="1">Antibiotics group</th><th align="center" rowspan="2" valign="top" colspan="1">
<italic>p</italic>&#x02010;value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">PSAL &#x02265;1.3&#x000a0;mm (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Q 25/Q75</th><th align="center" valign="top" rowspan="1" colspan="1">PSAL &#x02265;1.3&#x000a0;mm (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Q 25/Q75</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">
<italic>Intention to Treat Collective</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="char" char="." rowspan="1" colspan="1">7.8</td><td align="char" char="." rowspan="1" colspan="1">4.7/14.1</td><td align="char" char="." rowspan="1" colspan="1">5.3</td><td align="char" char="." rowspan="1" colspan="1">3.1/9.9</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264;3.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">7.2</td><td align="char" char="." rowspan="1" colspan="1">3.9/14.5</td><td align="char" char="." rowspan="1" colspan="1">5.8</td><td align="char" char="." rowspan="1" colspan="1">2.8/11.5</td><td align="char" char="." rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" rowspan="1" colspan="1">3.5&#x02013;6.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">8.7</td><td align="char" char="." rowspan="1" colspan="1">4.4/15.5</td><td align="char" char="." rowspan="1" colspan="1">4.8</td><td align="char" char="." rowspan="1" colspan="1">1.8/9.6</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;6.5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">2.2</td><td align="char" char="." rowspan="1" colspan="1">0.0/20.0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/6.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">
<italic>Per&#x02010;Protocol Collective</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="char" char="." rowspan="1" colspan="1">7.5</td><td align="char" char="." rowspan="1" colspan="1">4.5/14.4</td><td align="char" char="." rowspan="1" colspan="1">5.3</td><td align="char" char="." rowspan="1" colspan="1">3.2/9.7</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264;3.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">7.1</td><td align="char" char="." rowspan="1" colspan="1">3.8/14.5</td><td align="char" char="." rowspan="1" colspan="1">5.8</td><td align="char" char="." rowspan="1" colspan="1">3.1/10.7</td><td align="char" char="." rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" rowspan="1" colspan="1">3.5&#x02013;6.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">8.6</td><td align="char" char="." rowspan="1" colspan="1">4.3/15.6</td><td align="char" char="." rowspan="1" colspan="1">4.6</td><td align="char" char="." rowspan="1" colspan="1">1.9/8.8</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;6.5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/20.0</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/7.7</td><td align="char" char="." rowspan="1" colspan="1">0.004</td></tr></tbody></table><table-wrap-foot><fn id="jcpe12441-note-0007"><p>
<italic>p</italic>&#x02010;values are from the van Elteren tests comparing the differences in PSAL &#x02265;1.3&#x000a0;mm between placebo and antibiotic patients overall and in each subgroup.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jcpe12441-sec-0015"><title>Secondary outcomes</title><p>The median PSAL &#x02265;1.3&#x000a0;mm over the 27.5&#x000a0;months trial period according to the baseline probing depth categories (&#x02264;3.4&#x000a0;mm, 3.5&#x02013;6.4&#x000a0;mm, &#x02265;6.5&#x000a0;mm) are shown in Table&#x000a0;<xref rid="jcpe12441-tbl-0004" ref-type="table-wrap">4</xref>. For results of the PP&#x02010;collective see also Table&#x000a0;<xref rid="jcpe12441-tbl-0004" ref-type="table-wrap">4</xref>. Results of PSAL after applying a threshold of &#x02265;2&#x000a0;mm are shown in Table&#x000a0;<xref rid="jcpe12441-tbl-0005" ref-type="table-wrap">5</xref>.</p><table-wrap id="jcpe12441-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>The proportion (%) of sites per patient with new clinical attachment loss (PSAL) &#x02265;2&#x000a0;mm between baseline (visit 2) and the 27.5&#x000a0;months follow&#x02010;up (visit 12). PSAL is also analysed according to the baseline probing depth category (&#x02264;3.4&#x000a0;mm, 3.5&#x02013;6.4&#x000a0;mm, &#x02265;6.5&#x000a0;mm) of the site. PSAL is described by median (25% quantile Q25/75% quantile Q75)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Initial pocket probing depths</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo group</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Antibiotics group</th><th align="center" rowspan="2" valign="top" colspan="1">
<italic>p</italic>&#x02010;value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">PSAL &#x02265;2&#x000a0;mm (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Q 25/Q75</th><th align="center" valign="top" rowspan="1" colspan="1">PSAL &#x02265;2&#x000a0;mm (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Q 25/Q75</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">
<italic>Intention to Treat Collective</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="char" char="." rowspan="1" colspan="1">3.3</td><td align="char" char="." rowspan="1" colspan="1">1.5/6.7</td><td align="char" char="." rowspan="1" colspan="1">2.1</td><td align="char" char="." rowspan="1" colspan="1">0.7/4.0</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264;3.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">2.7</td><td align="char" char="." rowspan="1" colspan="1">0.9/6.5</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/4.4</td><td align="char" char="." rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" rowspan="1" colspan="1">3.5&#x02013;6.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">3.7</td><td align="char" char="." rowspan="1" colspan="1">1.4/8.3</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/4.5</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;6.5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/9.1</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/0.0</td><td align="char" char="." rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" colspan="6" rowspan="1">
<italic>Per&#x02010;Protocol Collective</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="char" char="." rowspan="1" colspan="1">3.2</td><td align="char" char="." rowspan="1" colspan="1">1.4/6.7</td><td align="char" char="." rowspan="1" colspan="1">2.2</td><td align="char" char="." rowspan="1" colspan="1">0.8/3.9</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264;3.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">2.6</td><td align="char" char="." rowspan="1" colspan="1">0.9/6.4</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">0.7/4.2</td><td align="char" char="." rowspan="1" colspan="1">0.068</td></tr><tr><td align="left" rowspan="1" colspan="1">3.5&#x02013;6.4&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">3.6</td><td align="char" char="." rowspan="1" colspan="1">1.5/8.3</td><td align="char" char="." rowspan="1" colspan="1">2.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/4.3</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;6.5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/9.1</td><td align="char" char="." rowspan="1" colspan="1">0.0</td><td align="char" char="." rowspan="1" colspan="1">0.0/2.0</td><td align="char" char="." rowspan="1" colspan="1">0.037</td></tr></tbody></table><table-wrap-foot><fn id="jcpe12441-note-0008"><p>
<italic>p</italic>&#x02010;values are from the van Elteren tests comparing the differences in PSAL &#x02265;1.3&#x000a0;mm between placebo and antibiotic patients overall and in each subgroup.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>At baseline (ITT&#x02010;collective), the median proportion of sites displaying PPD of &#x02265;5&#x000a0;mm (Fig.&#x000a0;<xref rid="jcpe12441-fig-0002" ref-type="fig">2</xref>b) was 15.7% (Q25 10.4%/Q75 27.8%) for the placebo and 17.5% (Q25 10.3%/Q75 27.8%) for the antibiotics group (<italic>p</italic>&#x000a0;=&#x000a0;0.66). At 27.5&#x000a0;month, % PPD of &#x02265;5&#x000a0;mm had decreased to 5.5% (Q25 1.7%/Q75 12.6%) in the placebo and to 2.1% (Q25 0.6%/Q75 5.8%) in the antibiotics group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p><p>The median proportion (ITT&#x02010;collective) of sites with attachment gain &#x02265;1.3&#x000a0;mm over the 27.5&#x000a0;months period was 12.2% (Q25 7.1%/Q75 23.0%) for the placebo and 19.4% (Q25 10.4%/Q75 32.7%) for the antibiotics group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Clinical attachment level overall improved over the study period: mean attachment gain was 0.4&#x000a0;&#x000b1;&#x000a0;0.7&#x000a0;mm for the placebo and 0.6&#x000a0;&#x000b1;&#x000a0;0.7&#x000a0;mm for the antibiotics group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). In both groups, this gain was considerably more pronounced at sites with initially advanced probing depths of &#x02265;6.5&#x000a0;mm (placebo 2.1&#x000a0;&#x000b1;&#x000a0;1.7&#x000a0;mm <italic>versus</italic> antibiotics 2.8&#x000a0;&#x000b1;&#x000a0;1.5&#x000a0;mm; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p><p>In summary, other secondary parameters, for example proportions of PPD and absolute PPD and bleeding on probing improved over the 27.5&#x000a0;months observation period, whereas the plaque index scores improved initially, but returned to baseline levels later (Table&#x000a0;<xref rid="jcpe12441-tbl-0003" ref-type="table-wrap">3</xref>).</p><p>The proportion of patients showing PPD &#x02265;5&#x000a0;mm at &#x02264;4 sites are shown in Table&#x000a0;<xref rid="jcpe12441-tbl-0006" ref-type="table-wrap">6</xref> and the corresponding PSAL values are presented in Table&#x000a0;<xref rid="jcpe12441-tbl-0007" ref-type="table-wrap">7</xref>.</p><table-wrap id="jcpe12441-tbl-0006" xml:lang="en" orientation="portrait" position="float"><label>Table 6</label><caption><p>Proportions (%) and absolute numbers (<italic>n</italic>) of patients showing &#x02264;4sites with pocket probing depth &#x02265;5&#x000a0;mm (yes/no) at baseline (visit 2), 2&#x000a0;months re&#x02010;evaluation (visit 4) and 27.5&#x000a0;months follow&#x02010;up (visit 12)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Intention to Treat Collective</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Baseline</th><th align="center" colspan="2" valign="top" rowspan="1">Re&#x02010;evaluation 2&#x000a0;months</th><th align="center" colspan="2" valign="top" rowspan="1">Follow&#x02010;up 27.5&#x000a0;months</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">Yes</th><th align="center" valign="top" rowspan="1" colspan="1">No</th><th align="center" valign="top" rowspan="1" colspan="1">Yes<xref ref-type="fn" rid="jcpe12441-note-0009">*</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">No</th><th align="center" valign="top" rowspan="1" colspan="1">Yes<xref ref-type="fn" rid="jcpe12441-note-0009">*</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">No</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Placebo group &#x02013; % (<italic>n</italic>)</td><td align="char" char=" " rowspan="1" colspan="1">0.4 (1)</td><td align="char" char=" " rowspan="1" colspan="1">99.6 (254)</td><td align="char" char=" " rowspan="1" colspan="1">24.9 (60)</td><td align="char" char=" " rowspan="1" colspan="1">75.1 (181)</td><td align="char" char=" " rowspan="1" colspan="1">36.5 (73)</td><td align="char" char=" " rowspan="1" colspan="1">63.5 (127)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotics group &#x02013; % (<italic>n</italic>)</td><td align="char" char=" " rowspan="1" colspan="1">0.8 (2)</td><td align="char" char=" " rowspan="1" colspan="1">99.2 (248)</td><td align="char" char=" " rowspan="1" colspan="1">39.9 (95)</td><td align="char" char=" " rowspan="1" colspan="1">60.1 (143)</td><td align="char" char=" " rowspan="1" colspan="1">63.1 (130)</td><td align="char" char=" " rowspan="1" colspan="1">36.9 (76)</td></tr></tbody></table><table-wrap-foot><fn id="jcpe12441-note-0009"><p>Statistically noticeable differences*, Fisher's exact test, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="jcpe12441-tbl-0007" xml:lang="en" orientation="portrait" position="float"><label>Table 7</label><caption><p>The proportion (%) of sites per patient with new clinical attachment loss (PSAL) &#x02265;1.3&#x000a0;mm between baseline (visit 2) or re&#x02010;evaluation (visit 4) and the 27.5&#x000a0;months follow&#x02010;up (visit 12). The PSAL was analysed separately for patients according to the presence or not of &#x02264;4 sites with pocket probing depth &#x02265;5&#x000a0;mm at 27.5&#x000a0;months follow&#x02010;up (visit 12). PSAL is described by median (25% quantile Q25/75% quantile Q75)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" colspan="2" valign="top">Intention to treat collective</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo group</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Antibiotics group</th><th align="center" rowspan="2" valign="top" colspan="1">
<italic>p</italic>&#x02010;values</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">PSAL &#x02265;1.3&#x000a0;mm (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Q 25/Q75</th><th align="center" valign="top" rowspan="1" colspan="1">PSAL &#x02265;1.3&#x000a0;mm (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Q 25/Q75</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Baseline visit 2</td><td align="left" rowspan="1" colspan="1">&#x02264;4 sites with PPD &#x02265;5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">5.1</td><td align="char" char="." rowspan="1" colspan="1">2.6/9.0</td><td align="char" char="." rowspan="1" colspan="1">4.3</td><td align="char" char="." rowspan="1" colspan="1">2.4/8.3</td><td align="char" char="." rowspan="1" colspan="1">0.246</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;4 sites with PPD &#x02265;5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">10.0</td><td align="char" char="." rowspan="1" colspan="1">5.9/16.3</td><td align="char" char="." rowspan="1" colspan="1">8.1</td><td align="char" char="." rowspan="1" colspan="1">4.1/12.3</td><td align="char" char="." rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="2" colspan="1">Re&#x02010;evaluation visit 4</td><td align="left" rowspan="1" colspan="1">&#x02264;4 sites with PPD &#x02265;5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">7.7</td><td align="char" char="." rowspan="1" colspan="1">4.2/12.8</td><td align="char" char="." rowspan="1" colspan="1">7.7</td><td align="char" char="." rowspan="1" colspan="1">4.2/11.9</td><td align="char" char="." rowspan="1" colspan="1">0.667</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;4 sites with PPD &#x02265;5&#x000a0;mm</td><td align="char" char="." rowspan="1" colspan="1">11.1</td><td align="char" char="." rowspan="1" colspan="1">7.1/18.5</td><td align="char" char="." rowspan="1" colspan="1">9.1</td><td align="char" char="." rowspan="1" colspan="1">5.9/15.6</td><td align="char" char="." rowspan="1" colspan="1">0.109</td></tr></tbody></table><table-wrap-foot><fn id="jcpe12441-note-0010"><p>
<italic>p</italic>&#x02010;values are from the van Elteren tests comparing the differences in PSAL &#x02265;1.3&#x000a0;mm between placebo and antibiotic patients in each subgroup.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jcpe12441-sec-0016"><title>Serious adverse events (ITT&#x02010;collective)</title><p>Overall, 90 SAE, 39 in the placebo and 43 in the antibiotic group were reported over the course of the study. Eight SAE occurred prior to medication intake. Seven patients dropped out due to un&#x02010;blinding following an SAE occurrence (Fig.&#x000a0;<xref rid="jcpe12441-fig-0001" ref-type="fig">1</xref>b). One case of anaphylactic reaction related to the study medication (antibiotics group) was reported. Other SAE and Medical Dictionary for Regulatory Activities codes were equally distributed between placebo and antibiotics group and not related to the study medication.</p></sec><sec id="jcpe12441-sec-0017"><title>Subjective perception of treatment (ITT&#x02010;collective)</title><p>At baseline, the mean OHIP scores were 39.2&#x000a0;&#x000b1;&#x000a0;27.2 for the placebo and 46.0&#x000a0;&#x000b1;&#x000a0;33.8 for the antibiotics group. These scores decreased in the course of the study to 32.2&#x000a0;&#x000b1;&#x000a0;29.4 and 32.9&#x000a0;&#x000b1;&#x000a0;29.4 for placebo and antibiotics patients with mean changes of &#x02212;5.5&#x000a0;&#x000b1;&#x000a0;21.3 and &#x02212;11.0&#x000a0;&#x000b1;&#x000a0;26.1 respectively. The effect size (Cohen's <italic>d</italic>) of the score changes from baseline to 27.5&#x000a0;months between the two groups was <italic>d</italic>&#x000a0;=&#x000a0;0.23 (95% CI 0.03; 0.44).</p></sec></sec><sec id="jcpe12441-sec-0018"><title>Discussion</title><p>In the presented patient sample, from a clinical point of view, both therapeutic approaches were very effective and the absolute clinical differences between placebo and antibiotics groups were small. The median proportion of sites with disease progression of about 7.6% in the placebo and 5.2% in the antibiotics group was low, as was the median proportion of residual deep periodontal pockets (e.g. % PPD &#x02265;5&#x000a0;mm; 5.5% <italic>versus</italic> 2.1% respectively). On the other hand it is noteworthy that the administration of the empiric antibiotic therapy as an adjunctive to mechanical debridement resulted in statistically noticeable better outcomes compared to placebo. The small absolute differences between the groups and the explicit statistical significance raise the question about the definition of treatment success and the appraisal of clinical relevance.</p><p>Retrospective cohort studies detected a higher risk of tooth loss with increasing proportions of persistent probing depths &#x02265;5&#x000a0;mm or &#x02265;6&#x000a0;mm (McGuire &#x00026; Nunn <xref rid="jcpe12441-bib-0029" ref-type="ref">1996</xref>, Matuliene et&#x000a0;al. <xref rid="jcpe12441-bib-0028" ref-type="ref">2008</xref>), therefore, those parameters are frequently used as surrogates for tooth loss. In most of the antibiotic studies surrogates such as changes of probing pocket depths or proportion of remaining deep pockets were used to determine treatment success (Loesche et&#x000a0;al. <xref rid="jcpe12441-bib-0025" ref-type="ref">1991</xref>, Winkel et&#x000a0;al. <xref rid="jcpe12441-bib-0038" ref-type="ref">2001</xref>, Feres et&#x000a0;al. <xref rid="jcpe12441-bib-0012" ref-type="ref">2012</xref>, Mombelli et&#x000a0;al. <xref rid="jcpe12441-bib-0030" ref-type="ref">2013</xref>). The majority of these studies attested positive effects for different adjunctive systemic antibiotic regimes on pocket reduction and therefore finally justified the prescription of antibiotics (Herrera et&#x000a0;al. <xref rid="jcpe12441-bib-0018" ref-type="ref">2002</xref>). However, our observation was that proper mechanical debridement alone prevents new attachment loss much more predictable than it reduces the proportion of patients displaying deep pockets below arbitrary levels. As an example, while the incidence of new attachment loss in the placebo and antibiotics groups were, irrespective of statistical differences, in a similar low range (Fig.&#x000a0;<xref rid="jcpe12441-fig-0002" ref-type="fig">2</xref> a), the large differences in outcome of both therapies concerning the proportion of patients showing PPD &#x02265;5&#x000a0;mm at &#x02264;4 sites would be doubtlessly interpreted as clinically meaningful (Table&#x000a0;<xref rid="jcpe12441-tbl-0006" ref-type="table-wrap">6</xref>). It would fit a patho&#x02010;physiological logic that in patients with PPD &#x02265;5&#x000a0;mm at only &#x02264;4 sites, the proportions of sites with further attachment loss should decrease, too. But as shown in Table&#x000a0;<xref rid="jcpe12441-tbl-0007" ref-type="table-wrap">7</xref>, the strong changes in the number of deep sites must not inevitably result in also strong lowered disease progression rates and furthermore depends on the chosen baseline point (visit 2 <italic>versus</italic> visit 4), too. This means that the estimation of clinical success and efficacy of a procedure strongly depends on the criteria used to define it (Lundgren et&#x000a0;al. <xref rid="jcpe12441-bib-0026" ref-type="ref">2001</xref>).</p><p>If periodontal therapy aims at maintaining teeth in function for a lifetime, a parameter should be selected which represents or is tantamount to disease progression. Ideally, true parameters should be used to evaluate success of a therapeutic approach. The true success parameter and clinical endpoint for periodontal therapy is possibly tooth loss, but beside others, the reasonable duration of prospective studies is too short to use tooth loss as an endpoint (Eickholz et&#x000a0;al. <xref rid="jcpe12441-bib-0009" ref-type="ref">2008</xref>). Due to that problem, ongoing attachment loss is therefore the most reasonable parameter next to tooth loss, because it reflects periodontal disease progression and may be assessed within reasonable periods of observation (Claffey &#x00026; Egelberg <xref rid="jcpe12441-bib-0003" ref-type="ref">1995</xref>, Hujoel et&#x000a0;al. <xref rid="jcpe12441-bib-0020" ref-type="ref">1999</xref>). Therefore, this parameter could be chosen to appraise the efficacy of a clinical procedure (Herrera et&#x000a0;al. <xref rid="jcpe12441-bib-0018" ref-type="ref">2002</xref>). Former studies showed that the rate of attachment loss is low in patients with moderate to severe periodontal disease participating in a stringent maintenance programme, and this makes this factor difficult to interpret in prospective studies with reasonable observation periods (Lindhe et&#x000a0;al. <xref rid="jcpe12441-bib-0024" ref-type="ref">1983</xref>). The dilemma is that very small differences in the proportions of sites with further attachment loss may be interpreted as negligible or may be interpreted as meaningful, because also small differences could add up to clinically relevant amounts over a certain period of time. However, it is questionable if the small differences found between the placebo and the antibiotics group in this study can be extrapolate in a linear way for, i.e., a decade.</p><p>So the question still remains: How clinically relevant are the findings of the present trial for the use of adjunctive systemic antibiotics in periodontal therapy? The patients' subjective perception of both regimes, for example OHIP score change, and the appearances of serious adverse events during the course of the study were similar in both groups. The overall low incidence of attachment loss and its small absolute difference between the groups would not really influence routine daily treatment. In contrast to that, the higher number of teeth with residual PPD &#x02265;5&#x000a0;mm in the placebo group could require a more laborious maintenance therapy. However, it is of crucial importance to consider the use of systemic antibiotics in non&#x02010;life threatening but widespread diseases in relation to the development of general antibiotic resistance. The increased appearance of bacterial resistance is strongly related to the frequency of antibiotic drug consumption (Costelloe et&#x000a0;al. <xref rid="jcpe12441-bib-0005" ref-type="ref">2010</xref>, Laxminarayan et&#x000a0;al. <xref rid="jcpe12441-bib-0023" ref-type="ref">2014</xref>). The Standing Medical Advisory Committee has recommended using the lowest number of systemic antibiotic courses possible (United Kingdom Department of Health <xref rid="jcpe12441-bib-0007" ref-type="ref">1998</xref>).</p><p>After weighing up the pros and cons of adjunctive administration amoxicillin and metronidazole in the treatment of moderate or severe chronic periodontitis, we found that a simple clinical cut off, from where this treatment regimen should be prescribed and is accompanied by reasonably foreseeable benefits for the patient, is obviously hard to define. Because there is no easy way out, obviously the clinical relevance of a therapeutic option like the prescription of systemic antibiotics must be estimated on different levels. For patients suffering from aggressive periodontitis, generalized severe chronic periodontitis, or disease progression despite proper mechanical therapy, antibiotic drug prescription as an adjunct to initial mechanical therapy is a relevant therapeutic option and may have additive effects (Goodson et&#x000a0;al. <xref rid="jcpe12441-bib-0014" ref-type="ref">2012</xref>). But besides such diagnosis&#x02010;related treatment decision making, a risk&#x02010;related therapeutic approach considered by the periodontist may be even more important (Wennstr&#x000f6;m et&#x000a0;al. <xref rid="jcpe12441-bib-0037" ref-type="ref">1990</xref>). A risk&#x02010;related approach could mean that, for example younger patients may benefit more from adjunctive amoxicillin and metronidazole than older patients showing a comparable severity of periodontal disease as expressed by clinical measurements. Similar clinical signs at not similar ages may express different susceptibilities to the disease and may lead to a diverging appraisal of the clinical relevance of therapeutic approaches. Therefore, the 40&#x02010;year&#x02010;old patient with 50% attachment loss and 50% PPDs &#x02265;5&#x000a0;mm at 28 teeth may require a different extend of therapy than a 65&#x02010;year&#x02010;old patient with identical clinical signs and amount of teeth, because the risks of both patients for further disease progression may be different. In this example, the younger patient may have a better chance retaining more teeth in his lifetime due to the more reduced PPDs and the slight reduction in further attachment loss after adjunctive antibiotics, whereas the older patient probably will not lose more teeth, if no antibiotics were prescribed. In other words, the clinical relevance of reducing PPDs or avoiding small amounts of further attachment loss with the help of adjunctive amoxicillin and metronidazole may be related to the patient's individual risks for periodontal disease. So it will remain the therapist's decision to prescribe adjunctive amoxicillin and metronidazole and judge the effect on periodontal disease progression in patients undergoing periodontal maintenance and against the background of antibiotic resistance as clinically relevant or not.</p><p>In conclusion, mechanical debridement is highly effective in the prevention of new attachment loss and improves the majority of other clinical parameters. Results of mechanical therapy were statistically significant improved by the prescription of adjunctive antibiotics, but these improvements depend on the outcome parameter and are of conflicting clinical relevance in real life. Against the background and danger of increasing microbiological resistance, it seems even more reasonable that for routine treatment of periodontitis therapists should consider the patient's overall risk for periodontal disease when making a decision for or against antibiotic prescription, and should be careful not to underestimate the effect of proper mechanical debridement and modification of behavioural risk factors. In the present trial, compared to placebo, the prescription of empiric adjunctive systemic amoxicillin plus metronidazole was highly effective in terms of PPD reduction, but showed little absolute, although statistical significant, reduction in further attachment loss in formerly untreated patients with moderate or severe chronic periodontitis.</p></sec><sec id="jcpe12441-sec-0020"><p>
<boxed-text position="anchor" content-type="box" id="jcpe12441-blkfxd-0001" orientation="portrait"><caption><title>Clinical Relevance</title></caption><p>
<italic>Scientific rationale for the study</italic>: Systemic antibiotics are established adjuncts for periodontal therapy. The uncritical use of antibiotics increases bacterial resistances. It is mandatory, that prescription of systemic antibiotics undergoes a critical appraisal of its clinical relevance on the course of periodontal disease.</p><p>
<italic>Principal findings</italic>: In the present trial, compared to placebo, the prescription of empiric adjunctive systemic amoxicillin plus metronidazole was highly effective in terms of PPD reduction, but showed small absolute, although statistical significant, reduction in further attachment loss in formerly untreated patients with moderate or severe chronic periodontitis.</p><p>
<italic>Practical implications</italic>: Therapists should consider the patient's overall risk for periodontitis when making a decision for or against antibiotic prescription, and should be careful not to underestimate the effect of proper mechanical debridement and modification of behavioural risk factors.</p></boxed-text>
</p></sec></body><back><ack id="jcpe12441-sec-0019"><title>Acknowledgements</title><p>We thank the members of the Center for Clinical Trials, Medical Faculty Muenster, Germany, for supporting the trial: Sonja Baier, Trude Butterfa&#x000df;&#x02010;Bahloul, J&#x000fc;rgen Grebe, Kerstin Hovestadt, Heidi Oellers, Anita Ripkens&#x02010;Reinhard and Gudrun W&#x000fc;rthwein. Finally, we thank Tess Blundell for copyediting the manuscript.</p><p>Last but not least, the authors are greatly indebted to collaborators and staff members represent the ABPARO&#x02010;Group for their successful work on this project. The members of the ABPARO&#x02010;Group were:</p><p>
<italic>Study center, University Hospital Muenster</italic>: Christina Elberg, Heike Frieling&#x02010;Braithwaite, Anna&#x02010;Maria Marx, Marie Christin Ohlmeier, Martin Sachs and Thomas Weniger.</p><p>
<italic>University Hospital Berlin</italic>: Peter Purucker, Marta Czownicka, Kathleen Kraatz, Nicole Pischon and Bernd&#x02010;Michael Kleber.</p><p>
<italic>University Hospital Dresden</italic>: Gerlinde Bruhn, Ihssan Khallili and Katrin Lorenz.</p><p>
<italic>University Hospital Frankfurt</italic>: Bettina Dannewitz, Katrin Nickles, Lasse R&#x000f6;llke, Susanne Scharf and Martin Wohlfeil.</p><p>
<italic>University Hospital Giessen</italic>: Heidi Fastnacht, Jose Roberto Gonzales and Tomas Cabrera&#x02010;Chica.</p><p>
<italic>University Hospital Greifswald</italic>: Jutta Daus and Jutta Fangh&#x000e4;nel.</p><p>
<italic>University Hospital Heidelberg</italic>: Raluca Cosgarea, Amelie Meyer&#x02010;B&#x000e4;umer, Nihad El Sayed, Sven Zehaczek and Nils Zimmermann.</p><p>
<italic>University Hospital Wuerzburg</italic>: Markus Bechtold, Yvonne Jockel&#x02010;Schneider and Simone Veihelmann.</p><p>
<italic>Institute of Biostatistics and Clinical Research, Medical Faculty Muenster</italic>: Andreas Faldum, Joachim Ger&#x000df; and Achim Heinecke.</p><p>
<italic>Clinical Pharmacy, University Hospital Dresden</italic>: Ina&#x02010;Maria Klut and Madeleine Schubert.</p><p>
<italic>Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Greifswald</italic>: Matthias Nauck, Astrid Petersmann and Helma Preez.</p><p>
<italic>Data Monitoring and Safety Board</italic>: Guido Knapp, Gregor Petersilka and Anne Sonntag.</p></ack><ref-list content-type="cited-references" id="jcpe12441-bibl-0001"><title>References</title><ref id="jcpe12441-bib-0001"><mixed-citation publication-type="journal" id="jcpe12441-cit-0001">
<collab collab-type="authors">AAP</collab>
(<year>2000</year>) <article-title>Parameters of care</article-title>. <source>Journal of Periodontology</source>
<volume>71</volume>, <fpage>856</fpage>&#x02013;<lpage>858</lpage> and 867&#x02013;9.<pub-id pub-id-type="pmid">10875691</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0002"><mixed-citation publication-type="journal" id="jcpe12441-cit-0002">
<string-name>
<surname>Berglundh</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Krok</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Liljenberg</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Westfelt</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Serino</surname>, <given-names>G.</given-names>
</string-name> &#x00026; <string-name>
<surname>Lindhe</surname>, <given-names>J.</given-names>
</string-name> (<year>1998</year>) <article-title>The use of metronidazole and amoxicillin in the treatment of advanced periodontal disease. A prospective, controlled clinical trial</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>25</volume>, <fpage>354</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">9650870</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0003"><mixed-citation publication-type="journal" id="jcpe12441-cit-0003">
<string-name>
<surname>Claffey</surname>, <given-names>N.</given-names>
</string-name> &#x00026; <string-name>
<surname>Egelberg</surname>, <given-names>J.</given-names>
</string-name> (<year>1995</year>) <article-title>Clinical indicators of probing attachment loss following initial periodontal treatment in advanced periodontitis patients</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>22</volume>, <fpage>690</fpage>&#x02013;<lpage>696</lpage>.<pub-id pub-id-type="pmid">7593699</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0004"><mixed-citation publication-type="journal" id="jcpe12441-cit-0004">
<string-name>
<surname>Cobb</surname>, <given-names>C. M.</given-names>
</string-name> (<year>1996</year>) <article-title>Non&#x02010;surgical pocket therapy: mechanical</article-title>. <source>Annals of Periodontology</source>
<volume>1</volume>, <fpage>443</fpage>&#x02013;<lpage>490</lpage>.<pub-id pub-id-type="pmid">9118268</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0005"><mixed-citation publication-type="journal" id="jcpe12441-cit-0005">
<string-name>
<surname>Costelloe</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Metcalfe</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lovering</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mant</surname>, <given-names>D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hay</surname>, <given-names>A. D.</given-names>
</string-name> (<year>2010</year>) <article-title>Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta&#x02010;analysis</article-title>. <source>British Medical Journal</source>
<volume>340</volume>, <fpage>c2096</fpage>. doi:<ext-link ext-link-type="doi" xlink:href="10.1136/bmj.c2096">10.1136/bmj.c2096</ext-link>.<pub-id pub-id-type="pmid">20483949</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0006"><mixed-citation publication-type="journal" id="jcpe12441-cit-0006">
<string-name>
<surname>Darveau</surname>, <given-names>R. P.</given-names>
</string-name> (<year>2010</year>) <article-title>Periodontitis: a polymicrobial disruption of host homeostasis</article-title>. <source>Nature Reviews Microbiology</source>
<volume>8</volume>, <fpage>481</fpage>&#x02013;<lpage>490</lpage>.<pub-id pub-id-type="pmid">20514045</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0007"><mixed-citation publication-type="miscellaneous" id="jcpe12441-cit-0007">
<collab collab-type="authors">Department of Health</collab>
. (<year>1998</year>) <article-title>The path of least resistance at</article-title>
<ext-link ext-link-type="uri" xlink:href="http://webarchive.nationalarchives.gov.uk/20130107105354/">http://webarchive.nationalarchives.gov.uk/20130107105354/</ext-link>
<ext-link ext-link-type="uri" xlink:href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4120729.pdf">http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4120729.pdf</ext-link>
</mixed-citation></ref><ref id="jcpe12441-bib-0008"><mixed-citation publication-type="journal" id="jcpe12441-cit-0008">
<string-name>
<surname>Ehmke</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Moter</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Beikler</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Milian</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Flemmig</surname>, <given-names>T. F.</given-names>
</string-name> (<year>2005</year>) <article-title>Adjunctive antimicrobial therapy of periodontitis: long&#x02010;term effects on disease progression and oral colonization</article-title>. <source>Journal of Periodontology</source>
<volume>76</volume>, <fpage>749</fpage>&#x02013;<lpage>759</lpage>.<pub-id pub-id-type="pmid">15898936</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0009"><mixed-citation publication-type="journal" id="jcpe12441-cit-0009">
<string-name>
<surname>Eickholz</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Kaltschmitt</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Berbig</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Reitmeir</surname>, <given-names>P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Pretzl</surname>, <given-names>B.</given-names>
</string-name> (<year>2008</year>) <article-title>Tooth loss after active periodontal therapy. 1: patient&#x02010;related factors for risk, prognosis, and quality of outcome</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>35</volume>, <fpage>165</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">18199150</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0010"><mixed-citation publication-type="journal" id="jcpe12441-cit-0010">
<string-name>
<surname>Eke</surname>, <given-names>P. I.</given-names>
</string-name>, <string-name>
<surname>Dye</surname>, <given-names>B. A.</given-names>
</string-name>, <string-name>
<surname>Wei</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Thornton&#x02010;Evans</surname>, <given-names>G. O.</given-names>
</string-name> &#x00026; <string-name>
<surname>Genco</surname>, <given-names>R. J.</given-names>
</string-name> (<year>2012</year>) <article-title>CDC Periodontal Disease Surveillance workgroup: prevalence of periodontitis in adults in the United States: 2009 and 2010</article-title>. <source>Journal of Dental Research</source>
<volume>91</volume>, <fpage>914</fpage>&#x02013;<lpage>920</lpage>.<pub-id pub-id-type="pmid">22935673</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0011"><mixed-citation publication-type="journal" id="jcpe12441-cit-0011">
<string-name>
<surname>van Elteren</surname>, <given-names>P. H.</given-names>
</string-name> (<year>1960</year>) <article-title>On the combination of independent two&#x02010;sample tests of Wilcoxon</article-title>. <source>Bulletin de L'Institut International de Statistique</source>
<volume>37</volume>, <fpage>351</fpage>&#x02013;<lpage>361</lpage>.</mixed-citation></ref><ref id="jcpe12441-bib-0012"><mixed-citation publication-type="journal" id="jcpe12441-cit-0012">
<string-name>
<surname>Feres</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Soares</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Mendes</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Silva</surname>, <given-names>M. P.</given-names>
</string-name>, <string-name>
<surname>Faveri</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Teles</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Socransky</surname>, <given-names>S. S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Figueiredo</surname>, <given-names>L. C.</given-names>
</string-name> (<year>2012</year>) <article-title>Metronidazole alone or with amoxicillin as adjuncts to non&#x02010;surgical treatment of chronic periodontitis: a 1&#x02010;year double&#x02010;blinded, placebo&#x02010;controlled, randomized clinical trial</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>39</volume>, <fpage>1149</fpage>&#x02013;<lpage>1158</lpage>.<pub-id pub-id-type="pmid">23016867</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0013"><mixed-citation publication-type="journal" id="jcpe12441-cit-0013">
<string-name>
<surname>Flemmig</surname>, <given-names>T. F.</given-names>
</string-name>, <string-name>
<surname>Milian</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Karch</surname>, <given-names>H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Klaiber</surname>, <given-names>B.</given-names>
</string-name> (<year>1998</year>) <article-title>Differential clinical treatment outcome after systemic metronidazole and amoxicillin in patients harboring <italic>Actinobacillus actinomycetemcomitans</italic> and/or <italic>Porphyromonas gingivalis</italic>
</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>25</volume>, <fpage>380</fpage>&#x02013;<lpage>387</lpage>.<pub-id pub-id-type="pmid">9650874</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0014"><mixed-citation publication-type="journal" id="jcpe12441-cit-0014">
<string-name>
<surname>Goodson</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Haffajee</surname>, <given-names>A. D.</given-names>
</string-name>, <string-name>
<surname>Socransky</surname>, <given-names>S. S.</given-names>
</string-name>, <string-name>
<surname>Kent</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Teles</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Hasturk</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Bogren</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Van Dyke</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Wennstrom</surname>, <given-names>J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Lindhe</surname>, <given-names>J.</given-names>
</string-name> (<year>2012</year>) <article-title>Control of periodontal infections: a randomized control trial I. The primary outcome attachment gain and pocket depth reduction at treated sites</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>39</volume>, <fpage>526</fpage>&#x02013;<lpage>536</lpage>.<pub-id pub-id-type="pmid">22512461</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0015"><mixed-citation publication-type="journal" id="jcpe12441-cit-0015">
<string-name>
<surname>Guerrero</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>, <given-names>G. S.</given-names>
</string-name>, <string-name>
<surname>Nibali</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Suvan</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Moles</surname>, <given-names>D. R.</given-names>
</string-name>, <string-name>
<surname>Laurell</surname>, <given-names>L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Tonetti</surname>, <given-names>M. S.</given-names>
</string-name> (<year>2005</year>) <article-title>Adjunctive benefits of systemic amoxicillin and metronidazole in non&#x02010;surgical treatment of generalized aggressive periodontitis: a randomized placebo&#x02010;controlled clinical trial</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>32</volume>, <fpage>1096</fpage>&#x02013;<lpage>1107</lpage>.<pub-id pub-id-type="pmid">16174275</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0016"><mixed-citation publication-type="journal" id="jcpe12441-cit-0016">
<string-name>
<surname>Haffajee</surname>, <given-names>A. D.</given-names>
</string-name>, <string-name>
<surname>Socransky</surname>, <given-names>S. S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Gunsolley</surname>, <given-names>J. C.</given-names>
</string-name> (<year>2003</year>) <article-title>Systemic anti&#x02010;infective periodontal therapy. A systematic review</article-title>. <source>Annals of Periodontology</source>
<volume>8</volume>, <fpage>115</fpage>&#x02013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">14971252</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0017"><mixed-citation publication-type="journal" id="jcpe12441-cit-0017">
<string-name>
<surname>Harks</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Harmsen</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Gravemeier</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Prior</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Koch</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Doering</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Petersilka</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Weniger</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Eickholz</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kocher</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Meyle</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Purucker</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Schlagenhauf</surname>, <given-names>U.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ehmke</surname>, <given-names>B.</given-names>
</string-name> (<year>2014</year>) <article-title>A concept for clinical research triggered by suggestions from systematic reviews about adjunctive antibiotics</article-title>. <source>Applied Clinical Research, Clinical Trials and Regulatory Affairs</source>
<volume>1</volume>, <fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="jcpe12441-bib-0018"><mixed-citation publication-type="journal" id="jcpe12441-cit-0018">
<string-name>
<surname>Herrera</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Sanz</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Jepsen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Needleman</surname>, <given-names>I.</given-names>
</string-name> &#x00026; <string-name>
<surname>Roldan</surname>, <given-names>S.</given-names>
</string-name> (<year>2002</year>) <article-title>A systematic review on the effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis patients</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>29</volume>(<issue>Suppl. 3</issue>), <fpage>136</fpage>&#x02013;<lpage>159</lpage>, discussion 160&#x02013;2.<pub-id pub-id-type="pmid">12787214</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0019"><mixed-citation publication-type="journal" id="jcpe12441-cit-0019">
<string-name>
<surname>Holtfreter</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Kocher</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Desvarieux</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Micheelis</surname>, <given-names>W.</given-names>
</string-name> (<year>2010</year>) <article-title>Prevalence of periodontal disease and treatment demands based on a German dental survey (DMS IV)</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>37</volume>, <fpage>211</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">20070861</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0020"><mixed-citation publication-type="journal" id="jcpe12441-cit-0020">
<string-name>
<surname>Hujoel</surname>, <given-names>P. P.</given-names>
</string-name>, <string-name>
<surname>Loe</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Anerud</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Boysen</surname>, <given-names>H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Leroux</surname>, <given-names>B. G.</given-names>
</string-name> (<year>1999</year>) <article-title>The informativeness of attachment loss on tooth mortality</article-title>. <source>Journal of Periodontology</source>
<volume>70</volume>, <fpage>44</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">10052769</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0021"><mixed-citation publication-type="journal" id="jcpe12441-cit-0021">
<string-name>
<surname>John</surname>, <given-names>M. T.</given-names>
</string-name>, <string-name>
<surname>Patrick</surname>, <given-names>D. L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Slade</surname>, <given-names>G. D.</given-names>
</string-name> (<year>2002</year>) <article-title>The German version of the Oral Health Impact Profile&#x02010;translation and psychometric properties</article-title>. <source>European Journal of Oral Sciences</source>
<volume>110</volume>, <fpage>425</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">12507215</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0022"><mixed-citation publication-type="journal" id="jcpe12441-cit-0022">
<string-name>
<surname>Lang</surname>, <given-names>N. P.</given-names>
</string-name>, <string-name>
<surname>Adler</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Joss</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Nyman</surname>, <given-names>S.</given-names>
</string-name> (<year>1990</year>) <article-title>Absence of bleeding on probing. An indicator of periodontal stability</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>17</volume>, <fpage>714</fpage>&#x02013;<lpage>721</lpage>.<pub-id pub-id-type="pmid">2262585</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0023"><mixed-citation publication-type="journal" id="jcpe12441-cit-0023">
<string-name>
<surname>Laxminarayan</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Duse</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wattal</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zaidi</surname>, <given-names>A. K.</given-names>
</string-name>, <string-name>
<surname>Wertheim</surname>, <given-names>H. F.</given-names>
</string-name>, <string-name>
<surname>Sumpradit</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Vlieghe</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Hara</surname>, <given-names>G. L.</given-names>
</string-name>, <string-name>
<surname>Gould</surname>, <given-names>I. M.</given-names>
</string-name>, <string-name>
<surname>Goossens</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Greko</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>So</surname>, <given-names>A. D.</given-names>
</string-name>, <string-name>
<surname>Bigdeli</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tomson</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Woodhouse</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Ombaka</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Peralta</surname>, <given-names>A. Q.</given-names>
</string-name>, <string-name>
<surname>Qamar</surname>, <given-names>F. N.</given-names>
</string-name>, <string-name>
<surname>Mir</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Kariuki</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bhutta</surname>, <given-names>Z. A.</given-names>
</string-name>, <string-name>
<surname>Coates</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bergstrom</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Wright</surname>, <given-names>G. D.</given-names>
</string-name>, <string-name>
<surname>Brown</surname>, <given-names>E. D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Cars</surname>, <given-names>O.</given-names>
</string-name> (<year>2014</year>) <article-title>Antibiotic resistance&#x02010;the need for global solutions</article-title>. <source>The Lancet Infectious Diseases</source>
<volume>13</volume>, <fpage>1057</fpage>&#x02013;<lpage>1098</lpage>. Erratum in 2014: <italic>The Lancet Infectious Diseases </italic>
<bold>14</bold>, 11.</mixed-citation></ref><ref id="jcpe12441-bib-0024"><mixed-citation publication-type="journal" id="jcpe12441-cit-0024">
<string-name>
<surname>Lindhe</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Haffajee</surname>, <given-names>A. D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Socransky</surname>, <given-names>S. S.</given-names>
</string-name> (<year>1983</year>) <article-title>Progression of periodontal disease in adult subjects in the absence of periodontal therapy</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>10</volume>, <fpage>433</fpage>&#x02013;<lpage>442</lpage>.<pub-id pub-id-type="pmid">6577035</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0025"><mixed-citation publication-type="journal" id="jcpe12441-cit-0025">
<string-name>
<surname>Loesche</surname>, <given-names>W. J.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>B. A.</given-names>
</string-name>, <string-name>
<surname>Morrison</surname>, <given-names>E. C.</given-names>
</string-name>, <string-name>
<surname>Caffesse</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hujoel</surname>, <given-names>P. P.</given-names>
</string-name> (<year>1991</year>) <article-title>Effects of metronidazole on periodontal treatment needs</article-title>. <source>Journal of Periodontology</source>
<volume>62</volume>, <fpage>247</fpage>&#x02013;<lpage>257</lpage>.<pub-id pub-id-type="pmid">2037955</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0026"><mixed-citation publication-type="journal" id="jcpe12441-cit-0026">
<string-name>
<surname>Lundgren</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Askl&#x000f6;w</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Thorstensson</surname>, <given-names>H.</given-names>
</string-name> &#x00026; <string-name>
<surname>H&#x000e4;refeldt</surname>, <given-names>A. M.</given-names>
</string-name> (<year>2001</year>) <article-title>Success rates in periodontal treatment as related to choice of evaluation criteria. Presentation of an evaluation criteria staircase for cost&#x02010;benefit use</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>28</volume>, <fpage>23</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">11142663</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0027"><mixed-citation publication-type="journal" id="jcpe12441-cit-0027">
<string-name>
<surname>Man&#x02010;Son&#x02010;Hing</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Laupacis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>O'Rourke</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Molnar</surname>, <given-names>F. J.</given-names>
</string-name>, <string-name>
<surname>Mahon</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Chan</surname>, <given-names>K. B.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wells</surname>, <given-names>G.</given-names>
</string-name> (<year>2002</year>) <article-title>Determination clinical importance of study results</article-title>. <source>Journal of General Internal Medicine</source>
<volume>17</volume>, <fpage>469</fpage>&#x02013;<lpage>476</lpage>.<pub-id pub-id-type="pmid">12133163</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0028"><mixed-citation publication-type="journal" id="jcpe12441-cit-0028">
<string-name>
<surname>Matuliene</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Pjetursson</surname>, <given-names>B. E.</given-names>
</string-name>, <string-name>
<surname>Salvi</surname>, <given-names>G. E.</given-names>
</string-name>, <string-name>
<surname>Schmidlin</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Br&#x000e4;gger</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Zwahlen</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Lang</surname>, <given-names>N. P.</given-names>
</string-name> (<year>2008</year>) <article-title>Influence of residual pockets on progression of periodontitis and tooth loss: results after 11&#x000a0;years of maintenance</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>35</volume>, <fpage>685</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">18549447</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0029"><mixed-citation publication-type="journal" id="jcpe12441-cit-0029">
<string-name>
<surname>McGuire</surname>, <given-names>M. K.</given-names>
</string-name> &#x00026; <string-name>
<surname>Nunn</surname>, <given-names>M. E.</given-names>
</string-name> (<year>1996</year>) <article-title>Prognosis versus actual outcome. II. The effectiveness of clinical parameters in developing an accurate prognosis</article-title>. <source>Journal of Periodontology</source>
<volume>67</volume>, <fpage>658</fpage>&#x02013;<lpage>665</lpage>.<pub-id pub-id-type="pmid">8832476</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0030"><mixed-citation publication-type="journal" id="jcpe12441-cit-0030">
<string-name>
<surname>Mombelli</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cionca</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Almaghlouth</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>D&#x000e9;caillet</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Courvoisier</surname>, <given-names>D. S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Giannopoulou</surname>, <given-names>C.</given-names>
</string-name> (<year>2013</year>) <article-title>Are there specific benefits of amoxicillin plus metronidazole in <italic>Aggregatibacter actinomycetemcomitans</italic>&#x02010;associated periodontitis? Double&#x02010;masked, randomized clinical trial of efficacy and safety</article-title>. <source>Journal of Periodontology</source>
<volume>84</volume>, <fpage>715</fpage>&#x02013;<lpage>724</lpage>.<pub-id pub-id-type="pmid">22873656</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0031"><mixed-citation publication-type="journal" id="jcpe12441-cit-0031">
<string-name>
<surname>O'Leary</surname>, <given-names>T. J.</given-names>
</string-name>, <string-name>
<surname>Drake</surname>, <given-names>R. B.</given-names>
</string-name> &#x00026; <string-name>
<surname>Naylor</surname>, <given-names>J. E.</given-names>
</string-name> (<year>1972</year>) <article-title>The plaque control record</article-title>. <source>Journal of Periodontology</source>
<volume>43</volume>, <fpage>38</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">4500182</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0032"><mixed-citation publication-type="journal" id="jcpe12441-cit-0032">
<string-name>
<surname>Paster</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<surname>Boches</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>Galvin</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Ericson</surname>, <given-names>R. E.</given-names>
</string-name>, <string-name>
<surname>Lau</surname>, <given-names>C. N.</given-names>
</string-name>, <string-name>
<surname>Levanos</surname>, <given-names>V. A.</given-names>
</string-name>, <string-name>
<surname>Sahasrabudhe</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Dewhirst</surname>, <given-names>F. E.</given-names>
</string-name> (<year>2001</year>) <article-title>Bacterial diversity in human subgingival plaque</article-title>. <source>Journal of Bacteriology</source>
<volume>183</volume>, <fpage>3770</fpage>&#x02013;<lpage>3783</lpage>.<pub-id pub-id-type="pmid">11371542</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0033"><mixed-citation publication-type="journal" id="jcpe12441-cit-0033">
<string-name>
<surname>Pavici&#x00107;</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>van Winkelhoff</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Douqu&#x000e9;</surname>, <given-names>N. H.</given-names>
</string-name>, <string-name>
<surname>Steures</surname>, <given-names>R. W.</given-names>
</string-name> &#x00026; <string-name>
<surname>de Graaff</surname>, <given-names>J.</given-names>
</string-name> (<year>1994</year>) <article-title>Microbiological and clinical effects of metronidazole and amoxicillin in <italic>Actinobacillus actinomycetemcomitans</italic>&#x02010;associated periodontitis. A 2&#x02010;year evaluation</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>21</volume>, <fpage>107</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">8144729</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0034"><mixed-citation publication-type="journal" id="jcpe12441-cit-0034">
<string-name>
<surname>Socransky</surname>, <given-names>S. S.</given-names>
</string-name>, <string-name>
<surname>Haffajee</surname>, <given-names>A. D.</given-names>
</string-name>, <string-name>
<surname>Cugini</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Kent</surname>, <given-names>R. L.</given-names>
<suffix>Jr</suffix>
</string-name> (<year>1998</year>) <article-title>Microbial complexes in subgingival plaque</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>25</volume>, <fpage>134</fpage>&#x02013;<lpage>144</lpage>.<pub-id pub-id-type="pmid">9495612</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0035"><mixed-citation publication-type="journal" id="jcpe12441-cit-0035">
<string-name>
<surname>Spellberg</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Talbot</surname>, <given-names>G. H.</given-names>
</string-name>, <string-name>
<surname>Brass</surname>, <given-names>E. P.</given-names>
</string-name>, <string-name>
<surname>Bradley</surname>, <given-names>J. S.</given-names>
</string-name>, <string-name>
<surname>Boucher</surname>, <given-names>H. W.</given-names>
</string-name> &#x00026; <string-name>
<surname>Gilbert</surname>, <given-names>D. N.</given-names>
</string-name> (<year>2008</year>) <article-title>Position paper: recommended design features of future clinical trials of antibacterial agents for community&#x02010;acquired pneumonia. Infectious Diseases Society of America</article-title>. <source>Clinical Infectious Diseases</source>
<volume>47</volume>(<issue>Suppl. 3</issue>), <fpage>S249</fpage>&#x02013;<lpage>S265</lpage>.<pub-id pub-id-type="pmid">19018610</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0036"><mixed-citation publication-type="journal" id="jcpe12441-cit-0036">
<string-name>
<surname>Tinoco</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Beldi</surname>, <given-names>M. I.</given-names>
</string-name>, <string-name>
<surname>Campedelli</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Lana</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Loureiro</surname>, <given-names>C. A.</given-names>
</string-name>, <string-name>
<surname>Bellini</surname>, <given-names>H. T.</given-names>
</string-name>, <string-name>
<surname>Rams</surname>, <given-names>T. E.</given-names>
</string-name>, <string-name>
<surname>Tinoco</surname>, <given-names>N. M.</given-names>
</string-name>, <string-name>
<surname>Gjermo</surname>, <given-names>P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Preus</surname>, <given-names>H. R.</given-names>
</string-name> (<year>1998</year>) <article-title>Clinical and microbiological effects of adjunctive antibiotics in treatment of localized juvenile periodontitis. A controlled clinical trial</article-title>. <source>Journal of Periodontology</source>
<volume>69</volume>, <fpage>1355</fpage>&#x02013;<lpage>1363</lpage>.<pub-id pub-id-type="pmid">9926765</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0037"><mixed-citation publication-type="journal" id="jcpe12441-cit-0037">
<string-name>
<surname>Wennstr&#x000f6;m</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Papapanou</surname>, <given-names>P. N.</given-names>
</string-name> &#x00026; <string-name>
<surname>Gr&#x000f6;ndahl</surname>, <given-names>K. A.</given-names>
</string-name> (<year>1990</year>) <article-title>Model for decision making regarding periodontal treatment needs</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>17</volume>, <fpage>217</fpage>&#x02013;<lpage>222</lpage>.<pub-id pub-id-type="pmid">2347946</pub-id></mixed-citation></ref><ref id="jcpe12441-bib-0038"><mixed-citation publication-type="journal" id="jcpe12441-cit-0038">
<string-name>
<surname>Winkel</surname>, <given-names>E. G.</given-names>
</string-name>, <string-name>
<surname>van Winkelhoff</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Timmerman</surname>, <given-names>M. F.</given-names>
</string-name>, <string-name>
<surname>van der Velden</surname>, <given-names>U.</given-names>
</string-name> &#x00026; <string-name>
<surname>van der Weijden</surname>, <given-names>G. A.</given-names>
</string-name> (<year>2001</year>) <article-title>Amoxicillin plus metronidazole in the treatment of adult periodontitis patients. A double&#x02010;blind placebo&#x02010;controlled study</article-title>. <source>Journal of Clinical Periodontology</source>
<volume>28</volume>, <fpage>296</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">11314884</pub-id></mixed-citation></ref></ref-list></back></article>